ATLAS ACS2-TIMI 51

ATLAS ACS 2-TIMI 51 was a phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating an oral, direct factor Xa inhibitor (rivaroxaban) in subjects following an acute coronary syndrome. Subjects received low-dose aspirin therapy (75 to 100 mg/day), and enrollment was stratified based upon the intent of the investigator to administer a thienopyridine [Stratum 1 (aspirin only) and Stratum 2 (aspirin plus a thienopyridine)]. Two different doses of rivaroxaban were tested: 2.5 mg twice a day and 5.0 mg twice a day.

DOWNLOAD PRIMARY RESULTS SLIDE SET (PDF)

Association of White Blood Cell Count and Bleeding in ACS (AHA 2019)

 

Key Study Publications

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19. Abstract